Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | PLN 15 | PLN 12 | PLN 17 | PLN 26 |
| % Growth | 20.3% | -26.8% | -33.7% | – |
| Cost of Goods Sold | PLN 43 | PLN 3 | PLN 4 | PLN 6 |
| Gross Profit | -PLN 29 | PLN 9 | PLN 13 | PLN 20 |
| % Margin | -191.4% | 72.8% | 78.1% | 77.1% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| G&A Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| SG&A Expenses | PLN 0 | PLN 0 | PLN 1 | PLN 1 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 1 | PLN 37 | PLN 50 | PLN 59 |
| Operating Expenses | PLN 1 | PLN 37 | PLN 51 | PLN 60 |
| Operating Income | -PLN 30 | -PLN 28 | -PLN 38 | -PLN 41 |
| % Margin | -198.9% | -223.1% | -222.6% | -158.6% |
| Other Income/Exp. Net | PLN 5 | -PLN 6 | PLN 12 | PLN 6 |
| Pre-Tax Income | -PLN 25 | -PLN 34 | -PLN 25 | -PLN 35 |
| Tax Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Net Income | -PLN 25 | -PLN 34 | -PLN 25 | -PLN 35 |
| % Margin | -165.6% | -271.4% | -149.3% | -137.2% |
| EPS | -1.1 | -1.5 | -1.09 | -1.52 |
| % Growth | 26.7% | -37.6% | 28.3% | – |
| EPS Diluted | -1.1 | -1.5 | -1.1 | -1.52 |
| Weighted Avg Shares Out | 22 | 22 | 23 | 23 |
| Weighted Avg Shares Out Dil | 22 | 22 | 23 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 1 | PLN 1 | PLN 2 | PLN 2 |
| Interest Expense | PLN 2 | PLN 3 | PLN 2 | PLN 2 |
| Depreciation & Amortization | PLN 3 | PLN 2 | PLN 2 | PLN 3 |
| EBITDA | -PLN 20 | -PLN 28 | -PLN 21 | -PLN 31 |
| % Margin | -132.7% | -228.8% | -125.1% | -120.1% |